With 2.43 million shares changed hands, the volume of the stock remained heavier than its average volume of 1.43 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $27.99 whereas the lowest price it dropped to was $25.03. The 52-week range on NKTR shows that it touched its highest point at $37.38 and its lowest point at $6.48 during that stretch. It currently has a 1-year price target of $90.67. Beta for the stock currently stands at 0.89.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of NKTR was up-trending over the past week, with a rise of 170.86%, but this was up by 132.98% over a month. Three-month performance surged to 133.33% while six-month performance rose 89.76%. The stock gained 85.23% in the past year, while it has gained 58.77% so far this year. A look at the trailing 12-month EPS for NKTR yields -9.53 with Next year EPS estimates of -12.11. For the next quarter, that number is -2.92. This implies an EPS growth rate of -19.62% for this year and -16.41% for next year. EPS is expected to decline by -16.75% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of 25.49%.
Float and Shares Shorts:
At present, 12.41 million NKTR shares are outstanding with a float of 11.96 million shares on hand for trading. On 2025-06-13, short shares totaled 0.6 million, which was 480.0 higher than short shares on 1747267200. In addition to Mr. Howard W. Robin as the firm’s CEO, President & Director, Ms. Sandra A. Gardiner serves as its CFO and Principal Financial & Accounting Officer.
Institutional Ownership:
Through their ownership of 0.67123 of NKTR’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2025-03-31, NKTR reported revenue of $10460000.0 and operating income of -$44366000.0. The EBITDA in the recently reported quarter was -$40800000.0 and diluted EPS was -$0.24.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for NKTR since 3 analysts follow the stock currently. There are 2 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 1 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With NKTR analysts setting a high price target of 120.0 and a low target of 69.0, the average target price over the next 12 months is 96.8. Based on these targets, NKTR could surge 364.4% to reach the target high and rise by 167.03% to reach the target low. Reaching the average price target will result in a growth of 274.61% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$6.86847 being high and -$12.39311 being low. For NKTR, this leads to a yearly average estimate of -$10.75065.
